CLINICAL_TRIALS
trial_result
· 2016-12-13
Clinical Trial Update: Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis [Phase 3]
Summary
Phase 3 trial comparing ABP 501 to adalimumab in moderate-to-severe rheumatoid arthritis demonstrated efficacy and safety results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2016-12-13